The nation of Zimbabwe has turned down a significant American health deal valued at 367 million US dollars (£272m) over five years due to the United States' request for confidential information.
This rejection was revealed after a internal memorandum dated December was disclosed, which showed President Emmerson Mnangagwa believed the deal was "lopsided".
A government spokesman has since explained that the US was demanding access to genetic material for scientific study and profit while was unwilling to guarantee the benefits from any future medical innovations.
"We will now turn to the difficult and regrettable task of winding down our support in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont in a statement.
Her embassy said the United States had provided over $1.9bn in health funding to Zimbabwe over the last twenty years.
A doctors' association in Zimbabwe has appealed for more dialogue to reach a agreement agreeable to both sides so the country's vital HIV treatment initiative can continue.
Broader Implications
Zimbabwe's decision follows a similar situation in Kenya, where a court suspended a similar health funding agreement after legal challenges were raised about the safety of citizens' health data.
After resuming office last year, US President Donald Trump has reduced foreign aid and shut down the US Agency for International Development (USAID).
USAID had administered aid for the US government, but Trump claimed its expenditure was "inefficient" and his administration was seeking direct bilateral agreements to enhance transparency and accountability.
Based on statements, Sixteen African countries have so far agreed to these new agreements, representing over $18.3bn in new funding.
Details of the Rejected Agreement
The money for Zimbabwe was intended to funded "combating HIV/Aids, tuberculosis, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"It is our view this cooperation would have delivered extraordinary advantages for Zimbabwean communities, especially the 1.2 million men, women and children presently on HIV treatment via US-supported initiatives," Tremont said.
However, government spokesperson Nick Mangwana maintained the proposed deal was "unfair".
"Zimbabwe was being asked to provide its genetic material and health information over an extended period, with no equivalent assurance of access to any medical innovations – like vaccines, diagnostics, or treatments – that might result from that shared data," he stated.
"Put simply, our nation would provide the basic resources for scientific discovery with no certainty that the end products would be available to our population if a future health crisis emerge."
National Interest and International Frameworks
He also pointed out that the American exit from the World Health Organization (WHO) and its push of one-on-one deals were undermining structures already established through the international health agency.
The spokesperson cited its Pandemic Benefit-Sharing system created to manage future global health emergencies.
"This system is intended to guarantee that when a nation contributes its samples, the resulting advantages – including vaccines and treatments – are shared equitably, not monopolised exclusively by those with the capability to develop them."
Zimbabwe's reservations over the US deal "are not meant as opposition to America," Mangwana stressed.
"We welcome ongoing dialogue with our US partners on how subsequent co-operation might be arranged in a way that honours the sovereignty and interests of both nations."
Medical Community Response
Medical experts expressed it understood the official position, but recommended that talks need to persist since much of the country's HIV programmes depended on external financing.
"If technical issues exist, including those relating to information security or agreement terms, these can frequently be addressed through detailed discussion and mutually agreed protections," it added.
The halted deal highlights the ongoing challenges between receiving crucial foreign assistance and safeguarding a country's data in an ever more data-driven world.